期刊文献+

基于Mn掺杂ZnS量子点温室磷光检测左氧氟沙星 被引量:4

Detection of Levofloxacin by room temperature phosphorescence method based on Mn doped Zn S quantum dots
在线阅读 下载PDF
导出
摘要 以3-巯基丙酸为稳定剂,采用水相合成法制备Mn掺杂Zn S量子点,由于左氧氟沙星(LVFX)的3-羰基与Mn掺杂Zn S量子点表面的二价金属离子形成配合物,使得Mn掺杂Zn S量子点发生温室磷光猝灭效应,从而构建了一种快速、灵敏检测人体体液中LVFX的新方法。在最佳条件下(p H 7.4,反应时间10 min),其线性关系△RTP=27.56c(LVFX)+52.002(R=0.995),线性范围0.5~100μmol/L,检出限0.35μmol/L,加标回收率96.2%~104.6%,可用于LVFX注射液与人体尿液中LVFX的快速测定。 By taking 3-mercaptopropionic acid( MPA) as the stabilizer and preparing Mn doped ZnS quantum dots( QDs) by means of water phase synthesis method,room temperature phosphorescence quenching effect was happened to the Mn doped ZnS quantum dots because of the coordination complex formulated by bivalent metal ions on the surface of 3-carbonyl in Levofloxacin( LVFX) and Mn doped ZnS quantum dots,thus,a new rapid and sensitive method to detect LVFX in human body fluid was developed. Under optimum conditions( pH 7. 4,reaction time 10 min),with a linear relationship of △RTP =27. 56c( LVFX) + 52. 002( R = 0. 995),linear scope of 0. 5 ~ 100 μmol/L,and the detection limit and standard addition recovery of 0. 35 μmol/L and 96. 2% ~ 104. 6%,respectively,this method can be used for rapid detection of LVFX injection and LVFX in human urine.
出处 《应用化工》 CAS CSCD 北大核心 2017年第9期1839-1843,共5页 Applied Chemical Industry
基金 国家自然科学基金项目(31272258) 国家教育部博士点联合基金项目(20111404110002) 山西省重点化学优势学科建设项目(912019)
关键词 Mn掺杂ZnS量子点 温室磷光 左氧氟沙星 Mn doped ZnS quantum dots room temperature phosphorescence Levofloxacin
作者简介 安昭琦(1992-),女,山西平遥人,山西师范大学硕士研究生,师从闫桂琴教授,主要从事生物分子化学方面的研究.电话:18735712170,E-mail:771411297@qq.com 通讯联系人:闫桂琴(1956-),教授,博士,主要从事植物分子生物学及生物分子化学等方面的研究.E-mall:gqyan2013@163.com
  • 相关文献

参考文献2

二级参考文献36

  • 1Nobaki Aoki, Toshimaru Usada, Yataka Koda, et al. Clinical pharmacology and efficacy of levofloxacin in elderly patients [J].Jap J Antibiot, 1992, 45 (5) :530- 537.
  • 2Kenichi Tanaka, Masanofi Iwamoto, et al. Laboratory and clinical studies on levofloxacin [J]. Jap J Antibiot, 1992, 45 (5):548 - 556.
  • 3Goodwin SD, Gallis HA, Chow AT, et al. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection [J]. Antimicrob Chemother, 1994, 38 (4) :799- 805.
  • 4J.M. Nelson, T.M. Chiller, J.H. Powers, et al., Fluoroquinolone?resistant Campylobacter species and the withdrawal of fluoroquino?lones from use in poultry: a public health success story, Clin. Infect. Dis. 44 (2007) 977-980.
  • 5S. Kawahara, Chemotherapeutic agents under study, Nippon Rinsho 56 (1998) 3096-3099.
  • 6Indian Pharmacopoeia, Indian Pharmacopoeia Commission, Ghazia?bad, India, 2010, pp. 1579-1581149-56.
  • 7United States Pharmacopoeia, United States Pharmacopoeial Con?vention, Rockville, MD, USA, 2009, pp. 87-93.
  • 8J. Bertino, D. Fish, The safety profile of the fluoroquinolones, Clin. Ther. 22 (2000) 798.
  • 9Y.H. Tsai, M.J. Bair, C.c. Hu, Determination of levofloxacin in human urine with capillary electrophoresis and fluorescence detector, J. Chin. Chern. Soc. 54 (2007) 991-995.
  • 10K.M. Kothekar, B. Jayakar, A.P. Khandhar, et al., Quantitative determination of levofloxacin and ambroxol hydrochloride in phar?maceutical dosage form by reversed - phase high performance liquid chromatography, Eurasian J. Anal. Chern. 2 (2007) 21-31.

同被引文献36

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部